Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 13/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 13/20 | 0.57 |
| ▸ | PDE4C | Q08493 | 13/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 13/20 | 0.57 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6403046 | 1.00 | PDE4A (0.57) | PDE4APDE4BPDE4CPDE4DGPR119 | |
| SCHEMBL6402428 | 1.00 | PDE4A (0.57) | PDE4APDE4BPDE4CPDE4DGPR119 | |
| SCHEMBL11383040 | 0.86 | GPR119 (0.53) | PDE4APDE4BPDE4CPDE4DGPR119 | |
| SCHEMBL1251645 | 0.79 | PDE4A (0.55) | PDE4APDE4BPDE4CPDE4DGPR119 | |
| SCHEMBL1251878 | 0.76 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DGPR119 | |
| SCHEMBL11092220 | 0.76 | GPR119 (0.60) | PDE4APDE4BPDE4CPDE4DGPR119 | |
| SCHEMBL6400925 | 0.75 | PDE3B (0.56) | PDE4APDE4BPDE4CPDE4DGPR119 | |
| SCHEMBL11781780 | 0.74 | PDE4A (0.59) | PDE4APDE4BPDE4CPDE4DGPR119 | |
| SCHEMBL4110471 | 0.73 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL4120473 | 0.73 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059658-A1 | Pyridazinone | BAYER AKTIENGESELLSCHAFT (DE) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059658-A1 | Pyridazinone | TYMP, TPMT, PDXK | PDE4A 784/4885PDE4B 934/4885PDE4C 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.